091990 — Celltrion Healthcare Co Share News
0.000.00%
HealthcareAdventurousLarge Cap
- KR₩12tn
- KR₩12tn
- KR₩2tn
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap
Brief: Celltrion Usa Says U.S. FDA Approval Of Zymfentra For Treatment Of People With Inflammatory Bowel Disease
Brief: Celltrion Healthcare To Acquire 45 Billion Won Worth Of Own Shares
Cigna to add three Humira biosimilars to drug reimbursement list (updated)
Brief: Celltrion Healthcare To Acquire 24 Billion Won Worth Of Own Shares
Celltrion launches biosimilar of AbbVie's blockbuster drug Humira in US
Brief: Celltrion Healthcare Announces Canadian Approval Of Vegzelma For Treatment Of Cancers
Refinitiv Newscasts - UK Day Ahead: New working year stalled by fresh strikes
Brief: Celltrion USA Announces Submission Of The Biologics License Application (BLA) Of Novel Subcutaneous Formulation Of Ct-P13 To U.S. Food And Drug Administration
EU watchdog warns on waning effectiveness of antibody COVID drugs (updated)
Brief: Hikma And Celltrion Healthcare Sign Exclusive Licensing Agreement For Ustekinumab For Middle East And North Africa Region
Media: Drug companies warn UK over 'penalising rebate' - FT
Brief: Celltrion USA Receives U.S. FDA Approval For Its Oncology Biosimilar Vegzelma For Treatment Of Six Types Of Cancer
Brief: European Commission Approves Celltrion Healthcare's Vegzelma For The Treatment Of Multiple Types Of Cancer
EU regulator okays COVID-19 treatments from GSK-Vir and Sobi (updated)
EU regulator okays COVID-19 treatments from GSK-Vir and Sobi